5-溴甲基-2-羟基-苯甲酸 | 501360-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴甲基-2-羟基-苯甲酸
• 英文名称: 5-bromomethyl-2-hydroxy-benzoic acid
• 英文别名: 3¹-Brom-6-oxy-m-toluylsaeure；5-Brommethyl-2-hydroxy-benzoesaeure；5-(Brommethyl)-salicylsaeure；exo-Brom-p-kresotinsaeure；5-(Bromomethyl)-2-hydroxybenzoic acid
• CAS: 501360-85-6
• 化学式: C₈H₇BrO₃
• 分子量: 231.046
• InChiKey: SGFUPZVGBKOKFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  380.2±37.0 °C(Predicted)
• 密度：
  1.778±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-溴甲基-2-羟基-苯甲酸 生成 2-羟基-5-(羟基甲基)苯甲酸
  参考文献：
  名称：

  Carpenter; Hunter, Journal of Applied Chemistry, 1953, vol. 3, p. 486,493

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 水杨酸 在 氢溴酸 作用下， 生成 5-溴甲基-2-羟基-苯甲酸
  参考文献：
  名称：

  DE113723

  摘要：

  公开号：

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2014099503A1

  公开（公告）日：2014-06-26

  The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

  本发明涉及式I的化合物[应在此处插入公式]及其药学上可接受的盐，用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式I化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARa拮抗剂的治疗有效量。该发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。
• TRIAZOLONE COMPOUNDS AND USES THEREOF
  申请人：INCEPTION 2, INC.

  公开号：US20150344446A1

  公开（公告）日：2015-12-03

  The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

  本发明涉及化合物I式及其药学上可接受的盐，其在前列腺癌、乳腺癌、结肠癌、胰腺癌、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的治疗中有用。本发明还包括含有化合物I式或其药学上可接受的盐的治疗有效量的药物组合物。本发明还涉及治疗前列腺癌、乳腺癌、卵巢癌、肝癌、肾癌、结肠癌、胰腺癌、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及通过给予选择性PPARα拮抗剂的治疗有效量来治疗前列腺癌、乳腺癌、结肠癌、胰腺癌、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。
• Triazolone compounds and uses thereof
  申请人：Tempest Therapeutics, Inc.

  公开号：US10568871B2

  公开（公告）日：2020-02-25

  The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

  本发明公开了式 I 的化合物 及其药学上可接受的盐，可用于治疗前列腺癌、乳腺癌、结肠癌、胰腺癌、人类慢性淋巴细胞白血病、黑色素瘤和其它癌症。本发明还包括药物组合物，其中包含治疗有效量的式 I 化合物或其药学上可接受的盐。本文公开的发明还涉及治疗前列腺癌、乳腺癌、卵巢癌、肝癌、肾癌、结肠癌、胰腺癌、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还进一步涉及治疗前列腺癌、乳腺癌、结肠癌、胰腺癌、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括施用治疗有效量的选择性 PPARα 拮抗剂。本发明的化合物和药物组合物还可用于治疗病毒感染，如 HCV 感染和 HIV 感染。
• TRIAZOLONE COMPOUNDS AND USES THEREOF
  申请人：Inception 2, Inc.

  公开号：US20170239223A1

  公开（公告）日：2017-08-24

  The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
• US9676754B2
  申请人：——

  公开号：US9676754B2

  公开（公告）日：2017-06-13